Engineered immune cells take on Hard-to-Treat cancers
Disease control
Recruiting now
This study is testing an experimental treatment called Anti-HER2 CAR-T cells for people with advanced solid tumors that have not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them to target the HER2 protein on cancer cells, a…
Phase: NA • Sponsor: UTC Therapeutics Inc. • Aim: Disease control
Last updated May 01, 2026 16:00 UTC